Equities analysts predict that ContraFect Corp (NASDAQ:CFRX) will announce ($0.09) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for ContraFect’s earnings, with estimates ranging from ($0.10) to ($0.08). ContraFect posted earnings of ($0.10) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 10%. The company is scheduled to announce its next earnings results on Thursday, November 14th.
According to Zacks, analysts expect that ContraFect will report full-year earnings of ($0.12) per share for the current fiscal year, with EPS estimates ranging from ($0.17) to ($0.03). For the next year, analysts expect that the business will post earnings of ($0.39) per share, with EPS estimates ranging from ($0.53) to ($0.25). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow ContraFect.
ContraFect (NASDAQ:CFRX) last announced its quarterly earnings data on Friday, August 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.09).
Several institutional investors have recently bought and sold shares of the business. Hartwell J M Limited Partnership grew its holdings in shares of ContraFect by 40.0% in the second quarter. Hartwell J M Limited Partnership now owns 140,000 shares of the biotechnology company’s stock worth $71,000 after acquiring an additional 40,000 shares during the period. Trellus Management Company LLC bought a new stake in shares of ContraFect in the second quarter worth $295,000. SG Americas Securities LLC bought a new stake in shares of ContraFect in the second quarter worth $343,000. White Pine Capital LLC grew its holdings in shares of ContraFect by 207.9% in the first quarter. White Pine Capital LLC now owns 907,430 shares of the biotechnology company’s stock worth $361,000 after acquiring an additional 612,700 shares during the period. Finally, Oracle Investment Management Inc. grew its holdings in shares of ContraFect by 13.1% in the second quarter. Oracle Investment Management Inc. now owns 6,356,649 shares of the biotechnology company’s stock worth $3,242,000 after acquiring an additional 735,450 shares during the period. 34.86% of the stock is owned by institutional investors and hedge funds.
NASDAQ:CFRX remained flat at $$0.42 during trading hours on Friday. The company’s stock had a trading volume of 306,956 shares, compared to its average volume of 476,686. The firm has a 50-day moving average price of $0.39 and a 200-day moving average price of $0.45. The firm has a market capitalization of $32.96 million, a PE ratio of -1.12 and a beta of 0.15. ContraFect has a 1-year low of $0.27 and a 1-year high of $2.63. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.15 and a quick ratio of 4.15.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Featured Article: What is the Fibonacci sequence?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.